Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 st
14 hours ago
- #NSCLC
- #ACROSS2-trial
- #EGFR-TKI
- ACROSS2 is a phase 3 study comparing aumolertinib plus carboplatin-pemetrexed vs. aumolertinib alone in EGFR-mutated NSCLC with co-existing tumor suppressor gene mutations.
- Combination therapy significantly improved median progression-free survival (19.78 vs. 16.53 months) and landmark PFS rates at 12, 18, and 24 months.
- Subgroup analysis showed a clear PFS benefit in patients with TP53 mutations.
- Grade 3+ adverse events were higher in the combination group (25.9% vs. 17.2%), but no drug-related deaths occurred.
- The study supports a genotype-directed, chemotherapy-targeted intensification approach for this molecularly defined population.